The global Auto-Injectors Market size is estimated to reach USD 20.59 billion in 2030 and is projected to grow at a CAGR of 14.4% from 2024 to 2030. Rising incidence of anaphylactic shock and other diseases such as diabetes, rheumatoid, & multiple sclerosis along with increasing approvals of auto-injectors are impelling growth.

Increasing prevalence of life-threatening allergies and rising demand for these devices are expected to aid growth. As per the Food Allergy Research & Education, around 200, 000 people every year need emergency medical care for allergic food reactions.

In addition, increasing approvals are anticipated to drive growth. For instance, in August 2018, U.S. FDA approved the first generic epinephrine auto-injector of Teva Pharmaceuticals to treat emergency allergic reactions, including anaphylaxis. Generic versions of EpiPen Jr & EpiPen of 0.15 mg & 0.3 mg, respectively, are indicated for pediatric and adult patients weighing more than 33 pounds.

Moreover, manufacturers are also developing new products and innovative technologies, which is expected to propel market growth. For instance, in June 2018, AbbVie GK launched Humira, which is a fully human antitumor necrosis factor alpha monoclonal antibody formulation with lock function & injection start & end alerts as well as an inspection window and injects completely in 10 seconds. Demand for these devices is increasing as they are designed in accordance with patient acceptance and compliance. Technological advancements are anticipated to make them more convenient and user-friendly. This is encouraging patients to adopt this technology for chronic illnesses.

List of Key Players in Auto-injectors Market

• Eli Lilly
• SHL Medical AG
• AbbVie, Inc.
• Amgen
• Owen Mumford
• Ypsomed
• Teva Pharmaceutical
• Biogen Idec
• Mylan N.V.
• Pfizer, Inc.
• Sanofi
• Gerresheimer

Related Press Release@ Auto-injectors Market Report

Auto-injectors Market Report Highlights

• Disposable auto-injectors emerged as the largest segment owing to convenience and ease of use
• Homecare settings accounted for largest share in end-use segment owing to increasing demand of products for daily administration of insulin
• North America dominated the auto-injectors market with largest share in 2018. Increasing demand for new technologies along with advanced healthcare infrastructure is expected to boost market growth during the forecast period
• Asia Pacific is expected to witness fastest growth during the forecast period owing to increasing number of diabetic patients
• Some of the key players are Eli Lilly; Scandinavian Health Ltd.; AbbVie, Inc.; Amgen; Owen Mumford; Ypsomed; Teva Pharmaceutical; Biogen Idec; Mylan N.V.; Pfizer, Inc.; and Sanofi

Auto-Injectors Market Report Scope

Auto-injectors Market Segmentation

Grand View Research has segmented the global auto-injectors market report based on type, indication, end use, and region:

Auto-injectors Type Outlook (Revenue, USD Million, 2018 - 2030­)

• Disposable auto-injectors
• Reusable auto-injectors
• • Prefilled
  • Empty

Auto-injectors Indication Outlook (Revenue, USD Million, 2018 - 2030)

• Rheumatoid Arthritis
• Multiple Sclerosis
• Diabetes
• Anaphylaxis
• Other Therapies

Auto-injectors End Use Outlook (Revenue, USD Million, 2018 - 2030)

• Homecare Settings
• Hospitals & Clinics
• Ambulatory Surgical Centers

Auto-injectors Region Outlook (Revenue, USD Million, 2018 - 2030)

• North America
• • U.S.
  • Canada
  • Mexico
• Europe
• • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
• • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
• • Brazil
  • Argentina
• Middle East & Africa
• • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Explore Horizon, the world's most expansive market research database